N Chimanlal Enterprises

Established in 1943, N Chimanlal Enterprises is a Mumbai-based export organization recognized by the Government of India, specifically the Ministry of Commerce & Industry. The company holds accreditations from Pharmexcil, FDA India, FPME, IMC, and FSSAI, reflecting its compliance with national standards. Over the decades, N Chimanlal Enterprises has built a strong reputation, establishing valuable connections with clients across Africa, Asia, the Caribbean, the Pacific, and Gulf countries.

The company operates under the Corporate Identification Number (CIN) U33110MH2005PTC158466, indicating its registration as a private limited entity in Mumbai, Maharashtra. While specific revenue figures are not publicly disclosed, N Chimanlal Enterprises has been recognized as a leading exporter in the pharmaceutical trade industry for over 75 years. The organization employs a dedicated team, with employee counts ranging from 11 to 50, as per available data. For more information, the company's official website is pilcare.com.

N Chimanlal Enterprises undertakes manufacturing operations, offering a portfolio of over 400 products across various therapeutic segments. This extensive range includes both branded and generic pharmaceuticals, catering to diverse healthcare needs. The company also exports its own brands, demonstrating its capability in product development and market expansion. While specific details about manufacturing plant locations and capacities are not publicly disclosed, N Chimanlal Enterprises emphasizes its commitment to quality and efficiency in its manufacturing processes.

Specific information regarding the CEO, CFO, and other key executives of N Chimanlal Enterprises is not publicly available. However, the company is known for its strong leadership and customer-focused approach, which have been instrumental in establishing valuable connections with clients across multiple continents. The leadership team is dedicated to upholding the company's values of financial discipline, integrity, and customer-centric operations, which have been ingrained in its employees, senior managers, and suppliers since its establishment in 1943.

N Chimanlal Enterprises has established a significant presence in various regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company holds accreditations from Pharmexcil, FDA India, FPME, IMC, and FSSAI, reflecting its compliance with international standards. While specific regulatory filings, approvals, and market access statuses in these regions are not publicly disclosed, the company's extensive export portfolio and global clientele suggest a robust compliance framework and successful market penetration.

N Chimanlal Enterprises has expanded its reach to emerging markets across Africa, Latin America, and Southeast Asia. The company's comprehensive export portfolio encompasses a wide range of products, identifying it as a primary supplier for pharmacies, hospitals, ministries of health, patients, and supermarkets. While specific details regarding WHO prequalification or other certifications enabling access to these markets are not publicly available, the company's global network and client base indicate a strong presence in these regions.

N Chimanlal Enterprises demonstrates a diversified geographic strategy, exporting to over 37 countries across five continents. This extensive reach mitigates concentration risk and showcases the company's ability to adapt to various market dynamics. The strategic direction focuses on expanding its global footprint while maintaining a strong presence in existing markets, ensuring sustained growth and resilience in the pharmaceutical export sector.

Specific details regarding N Chimanlal Enterprises' FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. However, the company's accreditations from FDA India and other regulatory bodies suggest a commitment to adhering to international standards and regulations. The absence of publicly disclosed FDA-specific information indicates that the company may not currently have direct FDA approvals or registrations.

N Chimanlal Enterprises holds accreditations from Pharmexcil, FDA India, FPME, IMC, and FSSAI, reflecting its compliance with various international standards. However, specific details regarding WHO prequalification, EU Good Manufacturing Practice (GMP) certificates, or European Directorate for the Quality of Medicines & HealthCare (EDQM) status are not publicly available. The company's global clientele and extensive export portfolio suggest adherence to international quality standards, though specific certifications are not disclosed.

N Chimanlal Enterprises operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. The company holds accreditations from FDA India, FPME, IMC, and FSSAI, indicating compliance with Indian regulatory standards. Specific details regarding CDSCO manufacturing licenses, state drug controller approvals, or export No Objection Certificates (NOCs) are not publicly disclosed. The company's longstanding presence in the pharmaceutical export industry suggests adherence to necessary regulatory requirements.

As of March 2026, there are no publicly available records of Form 483 observations, warning letters, or import alerts issued to N Chimanlal Enterprises. The absence of such records indicates a clean regulatory history, reflecting the company's commitment to maintaining high standards of compliance and quality in its operations.

N Chimanlal Enterprises operates in a competitive landscape with numerous pharmaceutical exporters globally. While specific competitors in overlapping categories are not publicly disclosed, the company's extensive product portfolio and global reach position it as a significant player in the pharmaceutical export sector. The company's focus on quality, customer-centric operations, and adherence to international standards contribute to its competitive edge in the market.

N Chimanlal Enterprises' key differentiators include its extensive product portfolio, encompassing over 300,000 products across 23+ segments, and its global reach, exporting to over 37 countries across five continents. The company's commitment to quality, customer-focused approach, and adherence to international standards further distinguish it in the pharmaceutical export industry.

N Chimanlal Enterprises currently focuses on pharmaceutical exports, offering a comprehensive range of branded and generic pharmaceuticals, over-the-counter products, surgical items, and allied products. The company's strategic direction emphasizes expanding its global footprint while maintaining a strong presence in existing markets. Future outlooks suggest continued growth and resilience in the pharmaceutical export sector, leveraging its diversified product portfolio and international accreditations.

N Chimanlal Enterprises has a longstanding track record in the pharmaceutical export industry, with over 75 years of experience. The company has established valuable connections with clients across multiple continents, indicating reliability and consistency in its export volumes. While specific reliability indicators are not publicly disclosed, the company's accreditations from various regulatory bodies suggest a commitment to maintaining high standards of quality and compliance.

Importers should verify the following certifications when considering N Chimanlal Enterprises as a supplier:

• FDA India Certification: Indicates compliance with Indian pharmaceutical manufacturing standards.

• FPME Accreditation: Reflects adherence to pharmaceutical manufacturing and export standards.

• IMC Membership: Demonstrates active participation in the Indian pharmaceutical industry.

• FSSAI Registration: Ensures compliance with food safety and standards for products that may include consumables.

To verify each certification, importers can contact the respective certifying bodies or request copies of the certificates directly from N Chimanlal Enterprises.

When conducting due diligence on N Chimanlal Enterprises, importers should consider the following steps:

• Verify Certifications: Confirm the validity of FDA India, FPME, IMC, and FSSAI certifications.

• Assess Product Portfolio: Review the range and quality of products offered to ensure they meet import requirements.

• Evaluate Supply Chain: Assess the reliability and efficiency of the company's supply chain and logistics capabilities.

• Check References: Contact existing clients to gather feedback on the company's performance and reliability.

• Review Compliance Records: Ensure the company has a clean regulatory history with no recent violations or warnings.